Francisco Sapunar

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 633 citations · Full text

Medicine, Oncology, Pharmacology +16

Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECT

Stephen Chia, William J. Gradishar, L. Mauriac et al. · Journal of Clinical Oncology · 2008 · 533 citations · Full text

Medicine, Oncology, Pharmacology +15

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

Tim Eisen, Chris Boshoff, Ian Mak et al. · British Journal of Cancer · 2000 · 342 citations · Full text

Medicine, Oncology, Pharmacology +13

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

Ivana Šestak, Jack Cuzick, Francisco Sapunar et al. · The Lancet Oncology · 2008 · 211 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The treatment of advanced renal cell cancer with high-dose oral thalidomide

Justin Stebbing, Charlotte Benson, Tim Eisen et al. · British Journal of Cancer · 2001 · 107 citations · Full text

Medicine, Oncology, Pharmacology +15